Skip to main content
Advertisement
Advertisement
ORKA
ORKA logo
Oruka Therapeutics, Inc. Common Stock
95.81
USD
Sponsored
-1.76
-1.80%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

94.50

-1.31
-1.37%

Oruka Therapeutics, Inc. Common Stock (ORKA) Earnings

ORKA Earnings Reports

Positive Surprise Ratio

ORKA beat 17 of 20 last estimates.

85%

Next Report

Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.69
Implied change from Q3 26 (Revenue/ EPS)
--
/
+9.52%
Implied change from Q4 25 (Revenue/ EPS)
--
/
+53.33%

Oruka Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 09, 2026, ORKA reported earnings of -0.63 USD per share (EPS) for Q3 26, missing the estimate of -0.61 USD, resulting in a -1.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.72% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.69 USD, with revenue projected to reach -- USD, implying an increase of 9.52% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Oruka Therapeutics, Inc. Common Stock reported EPS of -$0.63, missing estimates by -1.99%, and revenue of $0.00, 0% as expectations.
The stock price moved up 4.72%, changed from $104.56 before the earnings release to $109.50 the day after.
The next earning report is scheduled for Mar 10, 2027.
Based on -- analysts, Oruka Therapeutics, Inc. Common Stock is expected to report EPS of -$0.69 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement